# SetPoint Medical

received FDA approval in July 2025 for its neuroimmune modulation therapy for rheumatoid arthritis, the first clinically proven neuromodulation treatment for the condition, and its RESET-RA study was published in Nature Medicine in January 2026 demonstrating durable efficacy and safety;…

Source: https://en.bioecon.ru/companies/setpoint-medical/
Updated: 2026-08-15

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $432.4 million in total funding as of 2026-09-01 | https://salestools.io/en/blog/setpoint-medical-raises-115m-series-d, https://setpointmedical.com/setpoint-medical-raises-140-million-in-private-financing-and-expands-leadership-team-to-support-commercialization-strategy-for-rheumatoid-arthritis-therapy/ |
| Capacity | tens of thousands of units for several years [medium confidence] | https://valley.labusinessjournal.com/featured/setpoint-medical-hits-market/ |
| Regulatory approval | FDA approval received in July 2025 for the SetPoint System to treat rheumatoid arthritis | https://setpointmedical.com/setpoint-medical-receives-fda-approval-for-novel-neuroimmune-modulation-therapy-for-rheumatoid-arthritis/, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P240039, https://www.empr.com/news/fda-approves-neuroimmune-modulation-device-for-rheumatoid-arthritis/ |
| Production site | United States [medium confidence] | https://valley.labusinessjournal.com/featured/setpoint-medical-hits-market/ |
| Headcount | 103 employees as of 2026-09-01 | https://salestools.io/en/blog/setpoint-medical-raises-115m-series-d |

Independent sources: accessdata.fda.gov, empr.com, salestools.io, valley.labusinessjournal.com

## Technologies

- [Bioelectronic medicine & neuromodulation](https://en.bioecon.ru/technology/bioelectronic-medicine-neuromodulation/)